1. Review of the Evidence for Treatment of Children with Autism with Selective Serotonin Reuptake Inhibitors
- Author
-
West, Lis, Brunssen, Susan H., and Waldrop, Julee
- Subjects
Fluoxetine -- Analysis ,Autism -- Drug therapy ,Autism -- Analysis ,Phenols -- Analysis ,Family and marriage ,Health ,Health care industry ,Science and technology - Abstract
To authenticate to the full-text of this article, please visit this link: http://dx.doi.org/10.1111/j.1744-6155.2009.00196.x Byline: Lis West (1), Susan H. Brunssen (2), Julee Waldrop (2) Keywords: Antidepressants; autism; pervasive developmental disorder; pharmacotherapy; psychopharmacotherapy; selective serotonin reuptake inhibitors Abstract: PURPOSE. To review the potential role of serotonin dysregulation in autism and the efficacy of selective serotonin reuptake inhibitors (SSRIs) in treating core deficits and associated symptoms of autism in children. The literature was searched for reports of SSRI use in children with autism. Data are presented from prospective clinical trials that evaluated treatment outcomes. CONCLUSIONS. Some SSRIs show moderate success in managing specific behaviors. Only fluoxetine shows evidence of decreasing global autism severity. PRACTICE IMPLICATION. Definitive conclusions concerning selection criteria, dosage, safety, and efficacy cannot be drawn given the current state of evidence. Author Affiliation: (1)Carolina Pediatric Group, Fayetteville, NC (2)The University of North Carolina at Chapel Hill, School of Nursing, Chapel Hill, North Carolina, USA Article History: First received March 1, 2008; Revision received March 1, 2009; Accepted for publication March 18, 2009. Article note: jwaldrop@unc.edu, with a copy to the Editor: roxie.foster@UCDenver.edu
- Published
- 2009